New Zealand markets open in 4 hours 7 minutes
  • NZX 50

    12,700.50
    -2.47 (-0.02%)
     
  • NZD/USD

    0.7007
    +0.0032 (+0.46%)
     
  • ALL ORDS

    7,750.50
    -10.00 (-0.13%)
     
  • OIL

    70.37
    -0.89 (-1.25%)
     
  • GOLD

    1,810.60
    -7.50 (-0.41%)
     

Greenleaf Health Announces: Three Former FDA Officials Join the Firm

·4-min read

WASHINGTON, July 22, 2021--(BUSINESS WIRE)--Greenleaf Health, Inc. (Greenleaf), a leading Food and Drug Administration (FDA) regulatory consulting firm, today announces the addition of three former FDA officials to our team of experts. Julia Barrett, M.D., M.P.H., and Chris Leptak, M.D., Ph.D., will join the Drug and Biological Products Team as Executive Vice President and Senior Vice President, respectively. Grace McNally will join the Product Quality, Manufacturing, and Compliance Team as Senior Vice President.

Julia Barrett, M.D., M.P.H

Dr. Julia Barrett brings more than 28 years of clinical development and regulatory expertise to her role as Executive Vice President, Drug and Biological Products. Julia began her career as a clinical reviewer in the FDA’s Office of Vaccine Research and Review (OVRR) at the Center for Biologics Evaluation and Research (CBER). Prior to joining Greenleaf, Julia spent more than 17 years as a Senior Clinical Consultant at Biologics Consulting Group, where she focused on clinical product development and U.S. regulatory submissions.

Julia’s product expertise includes cell and gene therapy/regenerative medicine, protein therapeutics, allergy immunotherapy, vaccines, toxins, and microbiome-based products. Julia received her bachelor’s degree in biology from Smith College, an M.D. from Northwestern University, and an M.P.H. from George Washington University (GWU). She trained as a resident in internal medicine at the University of Minnesota and completed a fellowship in general internal medicine at GWU. Learn more about Julia Barrett.

Chris Leptak, M.D., Ph.D.

Dr. Chris Leptak joins Greenleaf following a distinguished 14-year career at the FDA, where much of his work focused on biomarker and diagnostic device utility in clinical trials and drug development. Most recently, Chris served as Associate Director, Regulatory Science in the Office of New Drugs (OND) within the FDA’s Center for Drug Evaluation and Research (CDER). During his FDA tenure, Chris led multiple programs and initiatives aimed at developing CDER’s approach to regulatory science, including as Director of the CDER Biomarker Qualification Program, Director of the OND Regulatory Science Program, and Acting Director of the Office of Drug Evaluation Science.

Chris received his undergraduate degree from Yale University and his M.D./Ph.D. at the University of California, San Francisco. Chris completed his residency in emergency medicine at Harvard’s combined Mass General and Brigham program. Learn more about Chris Leptak.

Grace McNally

Grace McNally brings more than 33 years of FDA service to her role as Senior Vice President, Regulatory Compliance at Greenleaf. Grace’s extensive FDA career is highlighted by multiple leadership positions, including her service as Director of the Division of Regulations, Guidance, and Standards within CDER’s Office of Policy for Pharmaceutical Quality; Branch Chief in the Office of Process and Facilities within CDER’s Office of Pharmaceutical Quality; and Compliance Officer within CDER’s Office of Compliance. Grace began her career at the FDA as a field investigator in the Philadelphia District and later joined the Denver District, where she specialized in pharmaceutical and medical device inspections. Grace received her B.S. in physics from Boston College. Learn more about Grace McNally.

About Greenleaf Health

Greenleaf is guided by experts with a combined total of more than 300 years of FDA experience. Barrett, Leptak, and McNally join a distinguished group of professionals at Greenleaf who previously served as leaders throughout the Agency, including: John Taylor, former FDA Counselor to the Commissioner and Principal Deputy Commissioner; Dr. Daniel Schultz, former Director of the FDA’s Center for Devices and Radiological Health (CDRH); Dr. Karen Midthun, former Director of the FDA’s Center for Biologics Evaluation and Research (CBER); Dr. John Jenkins, former Director of New Drugs for the FDA’s Center for Drug Evaluation and Research (CDER); Dr. Robert Meyer, former Director of CDER’s Office of Drug Evaluation II; Heather Rosecrans, former Director of CDRH’s 510(k) staff; David Elder, former Director of the FDA’s Office of Regional Affairs and Office of Enforcement; and Cynthia Schnedar, former Director of CDER’s Office of Compliance.

Greenleaf Health provides strategic and technical guidance to pharmaceutical, biotechnology, and medical device companies researching, developing, and manufacturing innovative solutions to pressing global public health challenges. Greenleaf’s robust blend of technical skill and FDA institutional knowledge enables the firm to provide reliable, objective guidance to companies developing medical products for the U.S. market.

For more information on Greenleaf Health, visit greenleafhealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005649/en/

Contacts

Taryn.Walpole@greenleafhealth.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting